Back to Search Start Over

Unsupervised consensus cluster analysis of [18F]-fluoroethyl-L-tyrosine positron emission tomography identified textural features for the diagnosis of pseudoprogression in high-grade glioma.

Authors :
Kebir S
Khurshid Z
Gaertner FC
Essler M
Hattingen E
Fimmers R
Scheffler B
Herrlinger U
Bundschuh RA
Glas M
Source :
Oncotarget [Oncotarget] 2017 Jan 31; Vol. 8 (5), pp. 8294-8304.
Publication Year :
2017

Abstract

Rationale: Timely detection of pseudoprogression (PSP) is crucial for the management of patients with high-grade glioma (HGG) but remains difficult. Textural features of O-(2-[18F]fluoroethyl)-L-tyrosine positron emission tomography (FET-PET) mirror tumor uptake heterogeneity; some of them may be associated with tumor progression.<br />Methods: Fourteen patients with HGG and suspected of PSP underwent FET-PET imaging. A set of 19 conventional and textural FET-PET features were evaluated and subjected to unsupervised consensus clustering. The final diagnosis of true progression vs. PSP was based on follow-up MRI using RANO criteria.<br />Results: Three robust clusters have been identified based on 10 predominantly textural FET-PET features. None of the patients with PSP fell into cluster 2, which was associated with high values for textural FET-PET markers of uptake heterogeneity. Three out of 4 patients with PSP were assigned to cluster 3 that was largely associated with low values of textural FET-PET features. By comparison, tumor-to-normal brain ratio (TNRmax) at the optimal cutoff 2.1 was less predictive of PSP (negative predictive value 57% for detecting true progression, p=0.07 vs. 75% with cluster 3, p=0.04).<br />Principal Conclusions: Clustering based on textural O-(2-[18F]fluoroethyl)-L-tyrosine PET features may provide valuable information in assessing the elusive phenomenon of pseudoprogression.

Details

Language :
English
ISSN :
1949-2553
Volume :
8
Issue :
5
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
28030820
Full Text :
https://doi.org/10.18632/oncotarget.14166